Glenmark Pharma a multinational company in October 2020 launched its generic version of Nintedanib (NINDANIB) in the India the drug is majorly used for the treatment of pulmonary fibrosis. Glenmark is a global pharmaceutical company and expertise in the area of respiratory has launched branded generic version at an affordable cost for the treatment of pulmonary fibrosis. The launch was focused on providing the patients with cost-effective treatment and enable doctors to treat a wider patient population in the country.
During the interview the company spoke person said that the Indian Drug regulatory body approved the Nintedanib that is aimed for the treatment of Idiopathic Pulmonary Fibrosis (IPF). There is gradual increase in the number of patients suffering from IPF disease. Starting of the treatment at early stage and continuity in it helps in lowering down the disease progression.
A lower monthly treatment cost therefore becomes crucial to ensure patients adhere to prescribed treatment in the long term. Nintedanib till now has been studied extensively in various controlled clinical trials that have established its efficacy and safety.
The company has it has rolled out two clinical trials in order to study the efficiency and safety of Nintedanib as a treatment of SARS-COV2 induced pulmonary fibrosis in moderate to severe COVID-19 patients. Availability of limited options of treatment for the interstitial lung diseases it poses a major threat to the country. The high price of newer treatments and the pill burden of existing options only add to poor patient adherence.
The introduction of NINDANIB there is a substantial reduction in cost of pills and patient spending on treatment in India. Pulmonary fibrosis (PF) is a respiratory condition characterized by the thickening and/or scarring of the lungs. This makes it difficult for oxygen to pass through the air sacs and into the bloodstream, causing symptoms such as shortness of breath and dry cough.
For more latest news Click Here